Racial differences in the association of pentraxin-3 with kidney dysfunction: The Multi-Ethnic Study of Atherosclerosis

Nephrology Dialysis Transplantation

Volumn 26, Issue 6, 2011, Pages 1903-1908

  Dubin, Ruth ^a   Shlipak, Michael ^a,b   Li, Yongmei ^b   Ix, Joachim ^c   De Boer, Ian H ^d   Jenny, Nancy ^e   Peralta, Carmen A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF VERMONT   (United States)

Author keywords

C reactive protein; estimated glomerular filtration rate by cystatin; pentraxin 3; race ethnicity; serum amyloid protein

Indexed keywords

C REACTIVE PROTEIN; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; PENTRAXIN 3; SERUM AMYLOID A; STATIN; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CAUCASIAN; CHINESE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ETHNICITY; FEMALE; GLOMERULUS FILTRATION RATE; HISPANIC; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RACE DIFFERENCE; SMOKING;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ETHNIC GROUPS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROGNOSIS; RENAL INSUFFICIENCY; SERUM AMYLOID P-COMPONENT;

EID: 79958106113     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq648     Document Type: Article

References (31)

1. Briet M, Bozec E, Laurent S et al. Arterial stiffness and enlargement in mild-to-moderate chronic kidney disease. Kidney Int 2006; 69: 350-7. (Pubitemid 43323087)
2. Foster MC, Keyes MJ, Larson MG et al. Relations of measures of endothelial function and kidney disease: the Framingham Heart Study. Am J Kidney Dis 2008; 52: 859-67.
3. Ghiadoni L, Cupisti A, Huang Y et al. Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol 2004; 17: 512-9. (Pubitemid 39302878)
4. Peralta CA, Adeney KL, Shlipak MG et al. Structural and functional vascular alterations and incident hypertension in normotensive adults: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol 2010; 171: 63-71.
5. Mantovani A, Garlanda C, Bottazzi B. Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine 2003; 21: S43-S47. (Pubitemid 36588649)
6. Rolph MS, Zimmer S, Bottazzi B et al. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002; 22: e10-e14.
7. Jenny NS, Arnold AM, Kuller LH et al. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2009; 29: 594-599.
8. Latini R, Maggioni AP, Peri G et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110: 2349-2354. (Pubitemid 39407338)
9. Suliman ME, Qureshi AR, Carrero JJ et al. The long pentraxin PTX- 3 in prevalent hemodialysis patients: associations with comorbidities and mortality. QJM 2008; 101: 397-405. (Pubitemid 351619248)
10. Tong M, Carrero JJ, Qureshi AR et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein- energy wasting, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 2007; 2: 889-897.
11. Bhuiyan AR, Li S, Li H et al. Distribution and correlates of arterial compliance measures in asymptomatic young adults: the Bogalusa Heart Study. Am J Hypertens 2005; 18: 684-691. (Pubitemid 40692437)
12. Duprez DA, Jacobs DR Jr, Lutsey PL et al. Race/ethnic and sex differences in large and small artery elasticity-results of the multi-ethnic study of atherosclerosis (MESA). Ethn Dis 2009; 19: 243-250.
13. Cutler JA, Sorlie PD,WolzMet al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008; 52: 818-827.
14. McClellan W, Tuttle E, Issa A. Racial differences in the incidence of hypertensive end-stage renal disease (ESRD) are not entirely explained by differences in the prevalence of hypertension. Am J Kidney Dis 1988; 12: 285-90.
15. Tarver-Carr ME, Powe NR, Eberhardt MS et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J Am Soc Nephrol 2002; 13: 2363-2370. (Pubitemid 34925247)
16. USRDS. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda: National Institutes of Health, National Institute of Digestive and Diabetes and Kidney Diseases, 2004; 2004.
17. Whittle JC, Whelton PK, Seidler AJ et al. Does racial variation in risk factors explain black-white differences in the incidence of hypertensive end-stage renal disease? Arch Intern Med 1991; 151: 1359-1364.
18. Bild DE, Bluemke DA, Burke GL et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol 2002; 156: 871-81. (Pubitemid 35215769)
19. Perkins BA, Nelson RG, Ostrander BE et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4- year follow-up study. J Am Soc Nephrol 2005; 16: 1404-1412. (Pubitemid 41716524)
20. Shlipak MG, Sarnak MJ, Katz R et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-2060. (Pubitemid 40664306)
21. Shlipak MG, Katz R, Sarnak MJ et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237-246. (Pubitemid 46768607)
22. Ix JH, Shlipak MG, Chertow GM et al. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007; 115: 173-179. (Pubitemid 46105715)
23. Stevens LA, Coresh J, Schmid CH et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51: 395-406. (Pubitemid 351273480)
24. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572. (Pubitemid 37430158)
25. Keller C, Katz R, Cushman M et al. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). BMC Nephrol 2008; 9: 9.
26. Foundation NK. NKF KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, Table 15: Definitions of Proteinuria and Albuminuria. 2002; http://www.kidney.org/professionals/KDOQI/ guidelines-ckd/ p4-class-g1.htm].
27. Souza DG, Amaral FA, Fagundes CT et al. The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice. Am J Pathol 2009; 174: 1309-1318.
28. Salio M, Chimenti S, De Angelis N et al. Cardioprotective function of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2008; 117: 1055-1064.
29. Norata GD, Marchesi P, Pulakazhi Venu VK et al. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 2009; 120: 699-708.
30. ExPASy. ExPASy Proteomics Server. Available from: http://www. expasy.ch/tools/pi-tool.html.
31. Bottazzi B, Doni A, Garlanda C et al. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 2009; 28: 157-183